GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone44-20-8047-5000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$43.10 billion
Profitability
Miscellaneous
Employees95,490
Next Earnings Date5/6/2020 (Estimated)
OptionableOptionable
GlaxoSmithKline (NYSE:GSK) Frequently Asked Questions
What is GlaxoSmithKline's stock symbol?
GlaxoSmithKline trades on the New York Stock Exchange (NYSE) under the ticker symbol "GSK."
How often does GlaxoSmithKline pay dividends? What is the dividend yield for GlaxoSmithKline?
GlaxoSmithKline declared a quarterly dividend on Thursday, February 6th. Stockholders of record on Friday, February 21st will be given a dividend of $0.5994 per share on Thursday, April 9th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 5.51%. The ex-dividend date is Thursday, February 20th. This is an increase from GlaxoSmithKline's previous quarterly dividend of $0.50. View GlaxoSmithKline's Dividend History.
How were GlaxoSmithKline's earnings last quarter?
GlaxoSmithKline plc (NYSE:GSK) released its earnings results on Wednesday, October, 30th. The pharmaceutical company reported $0.95 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.85 by $0.10. The pharmaceutical company had revenue of $11.57 billion for the quarter, compared to the consensus estimate of $11.34 billion. GlaxoSmithKline had a return on equity of 57.93% and a net margin of 13.72%. View GlaxoSmithKline's Earnings History.
When is GlaxoSmithKline's next earnings date?
What guidance has GlaxoSmithKline issued on next quarter's earnings?
GlaxoSmithKline updated its FY20 earnings guidance on Wednesday, February, 5th. The company provided EPS guidance of $1.19-1.23 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.20.
What price target have analysts set for GSK?
12 equities research analysts have issued 12-month target prices for GlaxoSmithKline's stock. Their forecasts range from $45.00 to $53.00. On average, they anticipate GlaxoSmithKline's stock price to reach $49.00 in the next year. This suggests a possible upside of 12.7% from the stock's current price. View Analyst Price Targets for GlaxoSmithKline.
What is the consensus analysts' recommendation for GlaxoSmithKline?
12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GlaxoSmithKline in the last year. There are currently 3 sell ratings, 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for GlaxoSmithKline.
Has GlaxoSmithKline been receiving favorable news coverage?
News articles about GSK stock have been trending positive on Thursday, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. GlaxoSmithKline earned a media sentiment score of 3.0 on InfoTrie's scale. They also assigned media stories about the pharmaceutical company a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for GlaxoSmithKline.
Are investors shorting GlaxoSmithKline?
GlaxoSmithKline saw a drop in short interest in January. As of January 31st, there was short interest totalling 6,650,000 shares, a drop of 8.5% from the January 15th total of 7,270,000 shares. Based on an average daily volume of 2,780,000 shares, the days-to-cover ratio is currently 2.4 days. Approximately 0.3% of the company's shares are sold short. View GlaxoSmithKline's Current Options Chain.
Who are some of GlaxoSmithKline's key competitors?
Some companies that are related to GlaxoSmithKline include Johnson & Johnson (JNJ), Roche Holdings AG Basel (RHHBY), Novartis (NVS), Merck & Co., Inc. (MRK), Pfizer (PFE), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), AbbVie (ABBV), Eli Lilly And Co (LLY), AstraZeneca (AZN), Sanofi (SNY), Bristol-Myers Squibb (BMY), Commonwealth Bank of Australia (CSLLY), Celgene (CELG) and Bayer (BAYRY).
What other stocks do shareholders of GlaxoSmithKline own?
Who are GlaxoSmithKline's key executives?
GlaxoSmithKline's management team includes the folowing people:
- Ms. Emma N. Walmsley, CEO & Director (Age 49)
- Mr. Simon P. Dingemans, CFO & Exec. Director (Age 55)
- Dr. Hal V. Barron, Chief Scientific Officer, Pres of R&D and Director (Age 56)
- Mr. Jack Bailey, Pres of US Pharmaceuticals
- Ms. Karenann K. Terrell, Chief Digital & Technology Officer (Age 57)
Who are GlaxoSmithKline's major shareholders?
GlaxoSmithKline's stock is owned by a number of of institutional and retail investors. Top institutional investors include FMR LLC (0.77%), Renaissance Technologies LLC (0.76%), State Street Corp (0.37%), Boston Partners (0.33%), Bank of America Corp DE (0.30%) and Hotchkis & Wiley Capital Management LLC (0.30%). View Institutional Ownership Trends for GlaxoSmithKline.
Which institutional investors are selling GlaxoSmithKline stock?
GSK stock was sold by a variety of institutional investors in the last quarter, including Bowen Hanes & Co. Inc., State Street Corp, Ariel Investments LLC, Alliancebernstein L.P., FMR LLC, Clark Estates Inc. NY, Diamond Hill Capital Management Inc. and Trust Co. of Virginia VA. View Insider Buying and Selling for GlaxoSmithKline.
Which institutional investors are buying GlaxoSmithKline stock?
GSK stock was purchased by a variety of institutional investors in the last quarter, including Boston Partners, Renaissance Technologies LLC, Hotchkis & Wiley Capital Management LLC, Captrust Financial Advisors, Euro Pacific Asset Management LLC, Douglas Lane & Associates LLC, Foundry Partners LLC and Goldman Sachs Group Inc.. View Insider Buying and Selling for GlaxoSmithKline.
How do I buy shares of GlaxoSmithKline?
Shares of GSK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is GlaxoSmithKline's stock price today?
One share of GSK stock can currently be purchased for approximately $43.49.
How big of a company is GlaxoSmithKline?
GlaxoSmithKline has a market capitalization of $108.52 billion and generates $43.10 billion in revenue each year. The pharmaceutical company earns $5.93 billion in net income (profit) each year or $3.17 on an earnings per share basis. GlaxoSmithKline employs 95,490 workers across the globe.View Additional Information About GlaxoSmithKline.
What is GlaxoSmithKline's official website?
How can I contact GlaxoSmithKline?
GlaxoSmithKline's mailing address is 980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0, TW8 9GS. The pharmaceutical company can be reached via phone at 44-20-8047-5000 or via email at [email protected]
MarketBeat Community Rating for GlaxoSmithKline (NYSE GSK)
MarketBeat's community ratings are surveys of what our community members think about GlaxoSmithKline and other stocks. Vote "Outperform" if you believe GSK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GSK will underperform the S&P 500 over the long term. You may vote once every thirty days.
